Report Store | Pharma intelligence
  • My Account
    • 0Shopping Cart
  • $0.00
  • Disease analysis
    • Anemias
    • Bacterial infections
    • Bleeding disorders
    • Brain Cancer
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Cerebrovascular diseases
    • Dermatology
    • Diabetes and diabetic complications
    • Gastroenterology
    • Gastrointestinal cancer
    • Head and Neck Cancer
    • Hypertension
    • Immunology and Inflammation
    • Infectious Diseases
    • Ischemic heart disease
    • Leukemia
    • Lung Cancer
    • Lymphoma
    • Oncology overview
    • Market Spotlight
    • Mens Health
    • Neurology
    • Oncology
    • Ophthalmology
    • Other Hematological Cancers
    • Other metabolic diseases
    • Other Solid Cancers
    • Pain
    • Psychiatry
    • Respiratory
    • Rheumatology
    • Skin cancer
    • Thrombosis
    • Urological cancer
    • Vaccines
    • Viral infections
    • Women’s Health
  • Strategy analysis
    • Bleeding disorders
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Commercial Strategy
    • Dealmaking and R&D
    • Head and Neck Cancer
    • Hot Topics
    • Infectious Diseases
    • KOL Insight
    • Leukemia
    • Lung Cancer
    • Manufacturing
    • Market Access
    • Neurology
    • Oncology
    • Outsourcing
    • Pricing & Reimbursement
    • R&D
    • Regulatory & Therapeutic Area
    • Trends
    • Urological cancer
  • Company analysis
    • Big Pharma
    • Emerging Pharma
    • Hot Topics
    • Japan Pharma
    • M&A Analysis
    • Mid Pharma
  • Drug analysis
    • A
    • B-C
    • D-F
    • G-L
    • M-O
    • P-R
    • S-T
    • U-Z
  • MedTech analysis
    • Allergy
    • Autoimmune / Immunology
    • Cardiovascular
    • Dermatology
    • Endocrine
    • ENT / Dental
    • Gastroenterology
    • Hearing
    • Hematology
    • Infectious Diseases
    • Metabolic
    • Neurology
    • Obstetrics / Gynecology
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Osteoporosis
    • Psychiatry
    • Renal
    • Respiratory
    • Rheumatology
    • Urology
  • Opinion & analysis
    • Business Development
    • Business Management
    • Clinical Trials
    • Digital Health
    • Cybersecurity
    • Compliance & Risk
    • Digital patient management
    • Digital policy & regulation
    • Finance & Pricing
    • Healthcare Innovation
    • ICT and Health
    • Leadership
    • Legislation Regulation & Policy
    • Market Access
    • Market Intelligence
    • Medical
    • Pharmaceutical Device
    • Pharmaceutical Research
    • Strategy & Innovation
    • Tech companies & Data
    • Tech & Pharma
  • Blogs
  • Search
  • Menu
You are here: Home > Strategy analysis > Market Access

Market Access


loader
  • Sort by Custom
    • Default
    • Custom
    • Name
    • Price
    • Date
    • Popularity (sales)
    • Average rating
    • Relevance
    • Random
    • Product ID
  • Click to order products descending
  • Display 30 Products per page
    • 15 Products per page
    • 30 Products per page
    • 45 Products per page
  • Value-Based Reimbursement in the US

    $2,995.00

    The US healthcare environment has been witnessing a slow albeit continuous shift from volume- to value-based reimbursement over the past couple of decades

    August 22, 2018
    Find out more
  • Value-Based Pricing – Evolution Rather Than Revolution

    $5,000.00

    A new value-based assessment (VBA) process is scheduled to come into effect in the UK in late 2014. There have been significant delays in determining how this would work in practice, reflecting VBA’s complexity.

    November 4, 2016
    Find out more
  • Vaccines Market Access in Emerging Markets

    $3,000.00

    Emerging markets account for approximately 18% of the global vaccines market, which is valued at more than $24bn. However, there are indications that this is an underestimate, and some observers forecast that the overall marketplace will reach $50bn by the mid2020s.

    August 29, 2019
    Find out more
  • US Specialty Drug Market Access

    $2,995.00

    High-touch specialty drugs for complex, chronic, high-cost, or rare diseases are an increasingly significant component of the US pharmaceutical market. A sharp growth in regulatory approvals accompanied by high prices has driven rapid increases in expenditure on specialty therapies by both public and private payers.

    November 4, 2016
    Find out more
  • US Regulatory Issues

    $2,995.00

    Key regulatory developments include the new Prescription Drug User Fee Act (PDUFA-V), which aims to improve interaction between the FDA and drug developers.

    November 2, 2016
    Find out more
  • US Pricing and Reimbursement

    $2,995.00

    Historically, few pricing controls have been implemented in the US; however, there is greater pressure to implement controls to help contain costs associated with the expansion of public healthcare provision.

    November 2, 2016
    Find out more
  • US Healthcare System Overview

    $2,995.00

    Continued growth in healthcare expenditure and the high number of individuals without health insurance coverage were the key drivers of the passage of the healthcare reform law.

    November 2, 2016
    Find out more
  • UK Regulatory Issues

    $2,995.00

    Recently there have been several new regulatory changes in the UK aimed at reducing the regulatory burden and allowing earlier access to medicines which are seen as a positive development for the pharmaceutical industry.

    November 2, 2016
    Find out more
  • UK Healthcare System Overview

    $2,995.00

    Reform of the NHS is underway despite widespread controversy and opposition from physicians, and will necessitate a change in the way pharmaceutical companies work with key stakeholders.

    November 2, 2016
    Find out more
  • UK Generics and Biosimilars

    $2,995.00

    Prescribing by international non-proprietary name, pharmacist incentives, and the high price differential between the brands and their generic alternatives are the key drivers of the generics market in the UK.

    November 2, 2016
    Find out more
  • Turkey Regulatory Issues

    $2,995.00

    The mandatory requirement imposed by the Turkish authorities for overseas manufacturers exporting pharmaceutical products to Turkey to obtain Good Manufacturing Practice (GMP) certification issued by the Turkish Ministry of Health is causing inordinate delays in the registration of new pharmaceutical products in Turkey. However, these delays can be resolved once the US Food and Drug […]

    November 1, 2016
    Find out more
  • Turkey Pricing and Reimbursement

    $2,995.00

    To contain overall healthcare expenditure and to rein in the rapid growth of pharmaceutical expenditure, in 2004 Turkey introduced price-setting procedures using an external reference system based on 5–10 reference countries (all from the EU).

    November 4, 2016
    Find out more
  • Trends in CNS Dealmaking, 2012–16

    $2,995.00

    Diseases of the central nervous system (CNS) offer considerable opportunity to drug developers and marketers.

    August 8, 2017
    Find out more
  • The Growing Impact of Real-World Evidence

    $2,995.00

    Real-world evidence (RWE) has become increasingly important in proving the value of drugs and differentiating them from their competition.

    July 14, 2017
    Find out more
  • The Evolution of Pharmaceutical Sales Strategies Continues

    $2,995.00

    Pharmaceutical sales forces have evolved from the traditional structure, which was dominated by considerable numbers of field-based representatives detailing a range of products to different physicians on a regular basis.

    November 1, 2016
    Find out more
  • Spotlight on Antibody-Drug Conjugates

    $2,995.00

    The first antibody-drug conjugate (ADC), Mylotarg, reached the market almost two decades ago. Since this time, the ADC field has undergone slow but transformative enhancements, with improvements to technologies and advancements in the pipeline leading to an invigoration of the field. The past couple of years have seen the approvals of three new ADCs: Polivy, Lumoxiti, and Besponsa, increasing the total number of ADCs approved by regulators worldwide to six. These approvals mark the start of a new era in which the ADC field is finally beginning to realize its full potential. With the ADC pipeline swelling to around 250 novel candidates in various stages of preclinical and clinical development, approvals for more ADCs appear firmly on the horizon.

    September 20, 2019
    Find out more
  • Spain Healthcare System and Drug Regulatory Analysis

    $2,995.00

    The market environment in Spain is extremely challenging, with cost-containment measures introduced in 2010–12 contributing to an overall reduction in pharmaceutical spending.

    November 2, 2016
    Find out more
  • Russia Pharmaceutical Market Dynamics

    $2,995.00

    With the Russian economy recovering from the recession experienced in 2009, the pharmaceutical market has also returned to growth.

    November 2, 2016
    Find out more
  • Russia Generics and Biosimilars

    $2,995.00
    • Despite high volume uptake, generics still account for only a small proportion of the total market value in Russia, driven by a lack of incentives for generic substitution and the significant originator/generic price differential.
    November 3, 2016
    Find out more
  • Renal Cell Cancer Pricing, Reimbursement, and Access

    $2,995.00

    There is moderate concern among payers regarding spend on renal cell cancer (RCC) drugs, but access restrictions remain mild.

    August 22, 2018
    Find out more
  • Psoriatic Arthritis: Market Access Pricing & Reimbursement

    $2,995.00

    Tumor necrosis factor (TNF)-alpha inhibitors Enbrel, Humira, and Remicade have long held dominant positions in the psoriatic arthritis market.

    October 17, 2016
    Find out more
  • Psoriasis Pricing, Reimbursement, and Access

    $2,995.00

    Launch of multiple IL inhibitors with impressive efficacy has significantly reduced unmet need in the disease, and also provided payers with leverage in price negotiations as they seek to control growing treatment cost.

    March 28, 2019
    Find out more
  • prostate-cancer-pricing-reimbursement-and-access_162106_10-2016

    Prostate Cancer: Market Access Pricing & Reimbursement

    $2,995.00

    The prostate cancer market has become saturated in the metastatic castration-resistant prostate cancer (CRPC) setting; the approval of second-generation antiandrogens, radiotherapies, and chemotherapies has resulted in a great deal of development targeting earlier stages of the disease.

    June 1, 2018
    Find out more
  • Poland Pricing and Reimbursement

    $2,995.00

    The average drug price in Poland is the lowest in the EU, mainly due to the high proportion of generic pharmaceuticals, low availability of innovative drugs, and high price pressure on reimbursed drugs.

    November 4, 2016
    Find out more
  • Ovarian Cancer Pricing, Reimbursement, and Access

    $2,995.00

    Ovarian cancer medicines have traditionally been subject to low restrictions, as most patients usually start and remain on inexpensive platinum-based therapies. However, beginning with the launch of vascular endothelial growth factor inhibitor Avastin, followed by poly (ADP-ribose) polymerase (PARP) inhibitor Lynparza, payers are seeing an uptick in spend for the indication.

    March 5, 2018
    Find out more
  • Orphan Drug Pricing and Reimbursement

    $2,995.00

    Orphan drugs account for a growing portion of payers’ budgets – and comprise some of the most expensive treatments available.

    November 4, 2016
    Find out more
  • Orphan Drug Access and Pricing in Emerging Markets

    $2,995.00

    This analysis covers the four major emerging regions of the Middle East and Africa, Latin America, Eastern Europe, and Asia-Pacific. Within these regions, relatively wealthier markets with a proven marketplace for orphan medicines have been prioritized.

    January 12, 2018
    Find out more
  • NOACs Pricing, Reimbursement, and Access

    $2,995.00

    A combination of the high cost of novel oral anticoagulants (NOACs) (relative to highly genericized vitamin K antagonists) and the large patient populations these drugs address, has resulted in this class of compounds being a top priority for European payers.

    May 10, 2017
    Find out more
  • New Pharma Models for a New Healthcare Era

    $2,995.00

    This analysis includes insights from eight interviewed experts from pharma, medical device, or digital health companies.

    December 20, 2018
    Find out more
  • Multiple Myeloma Pricing, Reimbursement, and Access

    $2,995.00

    Highlights: The budget impact of multiple myeloma is set to increase While multiple myeloma represents a relatively small patient population in comparison to other cancers, payers are concerned about the rising spend on the indication. New biologic therapies are increasingly gaining label expansions in earlier treatment lines, and with life expectancies improving, patients are requiring […]

    March 5, 2019
    Find out more
Page 1 of 4
Page 1 of 41234
  • Home
  • Terms and Conditions
  • Refund policy
  • Privacy Policy
  • Cookie Policy
  • Contact Us
  • About Us
  • Discounts
  • Market Spotlight – Reports
  • twitter
  • linkedin
  • Sitemap
Datamonitor Healthcare is part of Pharma intelligence Datamonitor Healthcare is a trading division of Datamonitor Limited, a company registered in England and Wales with company number 2306113 whose registered office is 5 Howick Place, London, SW1P 1WG. VAT GB365462636. Datamonitor Limited is part of Informa PLC.

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC
  • Informa PLC
  • ABOUT US
  • INVESTOR RELATIONS
  • TALENT
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726
informa
Call Back
Scroll to top